BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 15634518)

  • 1. [The effect of HER2/neu overexpression on p53 gene expression, cell proliferation and sensitivity to gamma-irradiation via the PI3K/Akt pathway in breast cancer cell MCF7].
    Zheng L; Ren JQ; Chen Q; Zhang HP; Zhu HG
    Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):594-7. PubMed ID: 15634518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Overexpression of HER2/neu downregulates wild p53 protein expression via PI3K and Ras/Raf/MEK/ERK pathways in human breast cancer cells].
    Zheng L; Ren JQ; Zhang L; Chen Q; Zhu HG
    Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):358-62. PubMed ID: 15363324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of wild-type p53 protein by HER-2/neu mediated PI3K pathway activation in human breast cancer cells: its effect on cell proliferation and implication for therapy.
    Zheng L; Ren JQ; Li H; Kong ZL; Zhu HG
    Cell Res; 2004 Dec; 14(6):497-506. PubMed ID: 15625017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells.
    Zhang W; Ding W; Chen Y; Feng M; Ouyang Y; Yu Y; He Z
    Acta Biochim Biophys Sin (Shanghai); 2011 Aug; 43(8):647-53. PubMed ID: 21712253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells.
    Sengupta S; Schiff R; Katzenellenbogen BS
    Breast Cancer Res Treat; 2009 Sep; 117(2):243-51. PubMed ID: 18807177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXO1A is a target for HER2-overexpressing breast tumors.
    Wu Y; Shang X; Sarkissyan M; Slamon D; Vadgama JV
    Cancer Res; 2010 Jul; 70(13):5475-85. PubMed ID: 20551062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway.
    Way TD; Kao MC; Lin JK
    J Biol Chem; 2004 Feb; 279(6):4479-89. PubMed ID: 14602723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival.
    Bacus SS; Altomare DA; Lyass L; Chin DM; Farrell MP; Gurova K; Gudkov A; Testa JR
    Oncogene; 2002 May; 21(22):3532-40. PubMed ID: 12032855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.
    She QB; Solit D; Basso A; Moasser MM
    Clin Cancer Res; 2003 Oct; 9(12):4340-6. PubMed ID: 14555504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth suppression of HER2-overexpressing breast cancer cells by berberine via modulation of the HER2/PI3K/Akt signaling pathway.
    Kuo HP; Chuang TC; Yeh MH; Hsu SC; Way TD; Chen PY; Wang SS; Chang YH; Kao MC; Liu JY
    J Agric Food Chem; 2011 Aug; 59(15):8216-24. PubMed ID: 21699261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
    Asanuma H; Torigoe T; Kamiguchi K; Hirohashi Y; Ohmura T; Hirata K; Sato M; Sato N
    Cancer Res; 2005 Dec; 65(23):11018-25. PubMed ID: 16322251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiRNA‑542‑3p downregulation promotes trastuzumab resistance in breast cancer cells via AKT activation.
    Ma T; Yang L; Zhang J
    Oncol Rep; 2015 Mar; 33(3):1215-20. PubMed ID: 25586125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of proline-rich Akt-substrate PRAS40 in cell survival pathway and carcinogenesis.
    Huang B; Porter G
    Acta Pharmacol Sin; 2005 Oct; 26(10):1253-8. PubMed ID: 16174443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth.
    Hermanto U; Zong CS; Wang LH
    Oncogene; 2001 Nov; 20(51):7551-62. PubMed ID: 11709727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous inhibition of EGFR and PI3K enhances radiosensitivity in human breast cancer.
    Li P; Zhang Q; Torossian A; Li ZB; Xu WC; Lu B; Fu S
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e391-7. PubMed ID: 22414288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of the phosphatidylinositol 3-kinase/Akt pathway prevents radiation-induced apoptosis in breast cancer cells.
    Söderlund K; Pérez-Tenorio G; Stål O
    Int J Oncol; 2005 Jan; 26(1):25-32. PubMed ID: 15586221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated PI3K/Akt/COX-2 pathway induces resistance to radiation in human cervical cancer HeLa cells.
    Xia S; Zhao Y; Yu S; Zhang M
    Cancer Biother Radiopharm; 2010 Jun; 25(3):317-23. PubMed ID: 20578837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential regulation of signal transduction pathways in wild type and mutated p53 breast cancer epithelial cells by copper and zinc.
    Ostrakhovitch EA; Cherian MG
    Arch Biochem Biophys; 2004 Mar; 423(2):351-61. PubMed ID: 15001399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lapatinib inhibits the activation of NF-κB through reducing phosphorylation of IκB-α in breast cancer cells.
    Ma C; Zuo W; Wang X; Wei L; Guo Q; Song X
    Oncol Rep; 2013 Feb; 29(2):812-8. PubMed ID: 23229346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatty acid synthase regulates proliferation and migration of colorectal cancer cells via HER2-PI3K/Akt signaling pathway.
    Li N; Bu X; Tian X; Wu P; Yang L; Huang P
    Nutr Cancer; 2012 Aug; 64(6):864-70. PubMed ID: 22860766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.